Key facts
- This page summarizes Suzanne Ildstad's Form 4 filing for Talaris Therapeutics, Inc. (TRML).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 02 Feb 2022, 17:04.
Suzanne Ildstad - 01 Feb 2022 Form 4 Insider Report for Talaris Therapeutics, Inc. (TRML)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- TRML
- Reported as of
- 01 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 02 Feb 2022, 17:04:13 UTC
- Next SEC filing
- 23 Aug 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Mary Kay Fenton, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Suzanne Ildstad filed Form 4 for Talaris Therapeutics, Inc. (TRML) on 02 Feb 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TALS
transaction
Common Stock
Gift
- Transaction value
- $0
- Shares
- -1,200,000
- Change %
- -25%
- Price
- $0.000000
- Shares after
- 3,606,446
- Date
- 17 Nov 2021
- Ownership
- Direct
- Footnotes
- F1
TALS
transaction
Common Stock
Gift
- Transaction value
- $0
- Shares
- +1,200,000
- Change %
- Price
- $0.000000
- Shares after
- 1,200,000
- Date
- 17 Nov 2021
- Ownership
- By GRAT
- Footnotes
- F1
TALS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 654,205
- Date
- 01 Feb 2022
- Ownership
- See Footnote
- Footnotes
- F2
TALS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 654,205
- Date
- 01 Feb 2022
- Ownership
- See Footnote
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TALS
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +150,000
- Change %
- Price
- $0.000000
- Shares after
- 150,000
- Date
- 01 Feb 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 150,000
- Exercise price
- $9.10
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Represents transfer of shares to the Reporting Person's GRAT.
Footnote F2
These shares are held in a trust for the benefit of the Reporting Person's son. The Reporting Persons son is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Footnote F3
These shares are held in a trust for the benefit of the Reporting Person's daughter. The Reporting Persons daughter is co-trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
Footnote F4
The shares underlying this option shall vest as follows: 25% shall vest on February 1, 2023; and the remaining shall vest in 36 equal monthly installments thereafter.